Clinical Trial Update: UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell Lymphomas [Phase 2]

View source ↗

Summary

Phase 2 trial of UCN-01 (7-Hydroxystaurosporine) for relapsed T-cell lymphomas was terminated, with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• T-cell Lymphoma

Drugs mentioned

• UCN-01 (7-hydroxystaurosporine)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Lymphoma, Large-Cell, Ki-1, Lymphoma, T-Cell | Phase 2 | Status: TERMINATED | Results posted: 2012-08-29